Status | Study |
Recruiting |
Study Name: CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Condition: ALK-negative Anaplastic Large Cell Lymphoma Peripherial T Cell Lymphoma,Not Otherwise Specif Date: 2012-12-04 Interventions: Drug: Cyclophosphamide 750mg/m2 |
Recruiting |
Study Name: CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study Condition: Peripheral T-cell Lymphoma NOS Anaplastic Large Cell Lymphoma, ALK-Negative Date: 2012-04-12 Interventions: Drug: Cyclophosphamide 750mg/m |
Recruiting |
Study Name: Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) Condition: T-cell Lymphoma Date: 2012-01-20 Interventions: Drug: Lenalidomide Lenalidomide |
Recruiting |
Study Name: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Condition: Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Date: 2011-03-23 Interventions: Drug: prednisone Given PO |
Active, not recruiting |
Study Name: Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma Condition: Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Date: 2011-03-23 Interventions: Drug: carfilzomib Given IV Other Names: |
Completed |
Study Name: RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Condition: Peripheral T Cell Lymphoma Unspecified Anaplastic Large Cell Lymphoma, ALK-negative Date: 2010-09-08 Interventions: Drug: RAD001 (Everolimus) Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO d |
Completed |
Study Name: Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Condition: Lymphoma Date: 2009-08-12 Interventions: Drug: cyclophosphamide Drug: fludarabine p |
Completed |
Study Name: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Condition: Peripheral T-cell Lymphoma (Not Otherwise Specified) Angioimmunoblasti Date: 2009-05-11 Interventions: Drug: panobinostat and bortezomib oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1. |
Recruiting |
Study Name: Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Condition: Peripheral T Cell Lymphoma, Unspecified Angioimmunoblastic Lymphadenop Date: 2008-07-25 Interventions: Biological: alemtuzumab Additi |
Completed |
Study Name: 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma Condition: Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Date: 2006-02-16 Interventions: Drug: gemcitabine hydrochloride |